<DOC>
	<DOCNO>NCT01089556</DOCNO>
	<brief_summary>This study investigate efficacy combination treatment duloxetine + pregabalin compare maximal dose drug monotherapy , patient diabetic peripheral neuropathic pain ( DPNP ) respond standard recommend dose either drug . It provide answer common clinical question , namely , good increase dose current monotherapy combine treatment early , patient respond standard dos duloxetine pregabalin .</brief_summary>
	<brief_title>A Study Painful Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Pain due bilateral peripheral neuropathy ( cause type 1 type 2 diabetes mellitus . Pain must begin foot , relatively symmetrical onset . Daily pain present 3 month [ assess question patient ] ) . Score least 4 24hour average pain severity score 11point Likert scale [ Brief Pain Inventory ( BPI ) Modified Short Form ] screen randomization . Patient currently receive treatment diabetic peripheral neuropathic pain ( DPNP ) receive treatment DPNP , drug pregabalin duloxetine , complete require washout Patient never receive treatment duloxetine pregabalin . ( However , short course le 15 day treatment , time previously , allow . ) Stable glycemic control , assess physician investigator , hemoglobin A1c ( HbA1c ) less equal 12 % screening . Have know hypersensitivity duloxetine pregabalin inactive ingredient contraindication use duloxetine pregabalin . Have uncontrolled narrowangle glaucoma . Have receive treatment monoamine oxidase inhibitor ( MAOI ) within 14 day prior randomization , potential need use MAOI study within 5 day discontinuation study drug . Have receive fluoxetine within 30 day prior randomization . Have acute liver injury ( hepatitis ) severe cirrhosis ( ChildPugh Class C ) . Have serum creatinine great equal 1.5 milligram per deciliter ( mg/dL ) creatinine clearance le 60 milliliter per minute ( mL/min ) , screen . Are judge clinically investigator suicidal risk define score 2 great Question 9 Beck Depression InventoryII ( BDIII ) , screen randomization Have historical exposure drug know cause neuropathy ( example , vincristine ) , history medical condition , include pernicious anemia hypothyroidism , could responsible neuropathy . Have pain clearly differentiated condition interfere assessment DPNP . Have serious unstable cardiovascular , hepatic , renal , respiratory hematological illness ; symptomatic peripheral vascular disease ; history seizure disorder ; medical ( include unstable hypertension clinically euthyroid ) psychological condition , opinion investigator , would compromise participation likely require hospitalization course study . Have receive nonpharmacological treatment pain within 14 day prior randomization , agree abstain nonpharmacological treatment study . Have history frequent and/or severe allergic reaction multiple medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>